The December 2024 replay wraps up the year with five previously posted episodes on autoimmune neurology. The episode begins with Drs. Michael R. Wilson and John Pluvinage discussing transcobalamin antibodies. The episode leads into an interview with Dr. Andrew McKeon, who talks about paraneoplastic CAMKV autoimmune encephalitis. In the third episode, Dr. Maarten Titulaer discusses long-term outcomes and rehab in NMDAR encephalitis. The episode continues with Prof. Zsolt Illes discussing the mortality of patients with AQP4 antibody–seropositive neuromyelitis optica spectrum disorder compared with that in the general population. In the final episode, Drs. Marius Ringelstein and Ilya Ayzenberg discuss the effectiveness and safety of Eculizumab in routine clinical care. Podcast Links: Transcobalamin receptor Antibodies in Autoimmune Vitamin B12 Central Deficiency Paraneoplastic CAMKV Autoimmune Encephalitis Long-Term Outcomes and Rehabilitation in Anti-NMDAR Encephalitis Mortality in a Danish NMO Cohort Eculizumab Use in Neuromyelitis Optica Spectrum Disorders Article Links: Transcobalamin Receptor Antibodies in Autoimmune Vitamin B12 Central Deficiency Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort Disclosures can be found at Neurology.org.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related